Science and Technology Studies Commons^™

Scientific Engagement At Fda: A Report To The Fda Science Board From The Scientific Engagement Subcommittee, Anthony Bahinski, Maria C. Friere, Mark R. Mclellan, Bruce M. Psaty, Dan M. Roden, Scott J. Steele

Biology Faculty Publications and Presentations

Maintaining active interactions with the broad external scientific community is vital for FDA to fulfill its expanding public health mission. It is essential for the Agency to be well positioned to address emerging areas of regulatory science and rapidly advancing technologies.

Scientific engagement also helps FDA accomplish its mission by increasing awareness of FDA’s responsibilities and helping with the Agency’s critical recruitment and succession planning needs. FDA uses a range of mechanisms for scientific exchange. The Subcommittee was charged with considering:

a. how FDA can improve its interface with the outside scientific community, particularly regarding public-private partnerships (PPPs) and fellowship …

Mission Possible: How Fda Can Move At The Speed Of Science, Margaret Anderson, Gail H. Cassell, Maria C. Freire, Lynn Goldman, Peter K. Honig, Frederick Kushner, Mark Mclellan, Barbara J. Mcneil, Martin A. Philbert, Bruce M. Psaty, Alan J. Russell, Ellen Sigal

Biology Faculty Publications and Presentations

In 2013, the Commissioner of Food and Drugs charged the Food and Drug Administration’s (FDA’s) Science Board, an advisory committee of national experts across various scientific disciplines, to make recommendations on areas deemed critical to the Agency’s ability to carry out its scientific mission. The Science Looking Forward Subcommittee was created to evaluate these three principal areas:

1. How FDA can meet emerging and future trends in science and technology
2. How FDA can better use collaborations to advance its mission and
3. How FDA can support a culture of scientific excellence and creativity.

The Subcommittee was also asked to assess progress since …